Glucagon, Glucagon-like Peptide (e.g., Glp-1, Etc.) Or Derivative Affecting Or Utilizing Patents (Class 514/7.2)
-
Publication number: 20140024586Abstract: The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in the methods of the present invention.Type: ApplicationFiled: October 3, 2013Publication date: January 23, 2014Applicant: ELI LILLY AND COMPANYInventors: Tamer COSKUN, Wolfgang GLAESNER
-
Publication number: 20140024585Abstract: A composition containing at least two of the following active substances A, B, C, wherein: A=at least one hormone stimulating the production of cAMP; B=at least one substance inhibiting the degradation of a cyclic nucleotide; C=at least one hormone stimulating the production of cGMP.Type: ApplicationFiled: April 11, 2011Publication date: January 23, 2014Inventors: Wolf Georg Forssmann, Rudolf Richter, Knut Adermann, Markus Meyer
-
Patent number: 8633156Abstract: The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the addition and/or substitution of negatively and positively charged amino acid residues and by an amidation of the C-terminal carboxy group of the B chain and histidine in position 8 of the insulin A chain. The invention also relates to the production and use thereof.Type: GrantFiled: June 22, 2010Date of Patent: January 21, 2014Assignee: Sanofi-Aventis Deutschland GmbHInventors: Paul Habermann, Gerhard Seipke, Roland Kurrle, Gunter Muller, Mark Sommerfeld, Norbert Tennagels, Georg Tschank, Ulrich Werner
-
Publication number: 20140018291Abstract: Methods are provided for administering an extended half-life GLP-1/GIP coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels in said patient.Type: ApplicationFiled: December 22, 2011Publication date: January 16, 2014Applicant: MARCADIA BIOTECH, INC.Inventors: Louis Vignati, Richard D. Dimarchi
-
Publication number: 20140011733Abstract: The invention relates to methods for treating metabolic disorders, including diabetes by using a combination of an acylated glucagon analogue and an insulin analogue. The invention also features a kit that includes an acylated glucagon analogue and an insuline analogue.Type: ApplicationFiled: January 20, 2012Publication date: January 9, 2014Applicant: Zealand Pharma A/SInventors: Keld Fosgerau, Ditte Riber
-
Publication number: 20140011738Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.Type: ApplicationFiled: June 18, 2013Publication date: January 9, 2014Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATIONInventor: Richard D. DiMARCHI
-
Publication number: 20140005106Abstract: The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating GLP-1 receptor in a subject in need of such stimulation, by administration of the formulation of the present invention.Type: ApplicationFiled: July 16, 2013Publication date: January 2, 2014Applicant: Emisphere Technologies, Inc.Inventors: Mohammed Amin KHAN, Bryan Edward Jones, John Mcneill McGill
-
Publication number: 20130345129Abstract: The present invention relates to an oligosaccharide chain added GLP-1 peptide that has higher stability in blood than that of GLP-1 and, preferably, exhibits higher activity of controlling blood-sugar levels than that of GLP-1. The present invention relates to an oligosaccharide chain added GLP-1 peptide having GLP-1 activity, wherein at least one amino acid is substituted with an oligosaccharide chain added amino acid, in: (a) GLP-1; (b) a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or (c) a GLP-1 analog.Type: ApplicationFiled: June 7, 2013Publication date: December 26, 2013Applicant: GLYTECH, INC.Inventors: YASUHIRO KAJIHARA, TAKASHI TSUJI, IZUMI SAKAMOTO, YURI NAMBU, KAZUHIRO FUKAE, KATSUNARI TEZUKA, HIROAKI ASAI
-
Patent number: 8614181Abstract: Method for increasing the shelf-life of a pharmaceutical composition for parenteral administration comprising a glucagon-like peptide which is prepared from a peptide product that has been subjected to treatment at a pH above neutral pH.Type: GrantFiled: November 5, 2009Date of Patent: December 24, 2013Assignee: Novo Nordisk A/SInventors: Claus Juul-Mortensen, Dorte Kot Engelund
-
Patent number: 8614182Abstract: This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity.Type: GrantFiled: January 31, 2012Date of Patent: December 24, 2013Assignee: Jiangsu Hansoh Pharmaceuticals Co., Ltd.Inventors: Yali Wang, Aifeng Lü, Changan Sun, Hengli Yuan
-
Publication number: 20130338068Abstract: The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from HOOC—(CH2)x—CO-*, and??Chem. 1: HOOC—C6H4-0-(CH2)y—CO-*,??Chem. 2: in which x is an integer in the range of 6-18, and y is an integer in the range of 3-17; and the linker comprises *-NH—(CH2)q—CH[(CH2)w—NH2]—CO-*,??Chem. 3: wherein q is an integer in the range of 0-5, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof.Type: ApplicationFiled: November 9, 2011Publication date: December 19, 2013Applicant: Novo Nordisk A/SInventors: Jacob Kofoed, Jesper Lau, Lars Linderoth, Patrick William Garibay, Thomas Kruse
-
Publication number: 20130336893Abstract: The present invention relates to exendin-4 peptide analogues and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.Type: ApplicationFiled: June 13, 2013Publication date: December 19, 2013Applicant: SANOFIInventors: Torsten HAACK, Andreas EVERS, Michael WAGNER, Bernd HENKEL, Siegfried STENGELIN
-
Publication number: 20130331323Abstract: A compound for controlling blood glucose level has a structure shown in Formula I: wherein R5-R8 are as defined herein. A method for controlling blood glucose level includes administering to a subject in need thereof a compound of Formula I. The method further includes administering to the subject a GLP-1 receptor ligand. The compound and the GLP-1 receptor ligand may be administered together. The compound may be Galanal A or Galanal B. The GLP-1 receptor ligand may be GLP-1 or exendin-4.Type: ApplicationFiled: June 6, 2013Publication date: December 12, 2013Applicant: Development Center for BiotechnologyInventors: Rey-Yuh Wu, Hui-Ling Chen, Yu-Yuan Wu, Jiann-Jyh Huang, Shoei-Sheng Lee, K-Lim King
-
Patent number: 8603970Abstract: The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the addition and/or substitution of negatively and positively charged amino acid residues and by an amidation of the C-terminal carboxy group of the B chain and histidine in position 8 of the insulin A chain. The invention also relates to the production and use thereof.Type: GrantFiled: June 22, 2010Date of Patent: December 10, 2013Assignee: Sanofi-Aventis Deutschland GmbHInventors: Paul Habermann, Gerhard Seipke, Roland Kurrle, Gunter Muller, Mark Sommerfeld, Norbert Tennagels, Georg Tschank, Ulrich Werner
-
Patent number: 8603972Abstract: The invention relates to protracted GLP-1 compounds and therapeutic uses thereof.Type: GrantFiled: March 20, 2006Date of Patent: December 10, 2013Assignee: Novo Nordisk A/SInventors: Jesper Lau, Florencio Zaragoza Dorwald, Lauge Schaffer, Thomas Kruse Hansen
-
Publication number: 20130324463Abstract: The present invention relates to the use of a certain DPP-4 inhibitor for modifying food intake and regulating food preference.Type: ApplicationFiled: May 21, 2013Publication date: December 5, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Thomas KLEIN, Michael MARK
-
Publication number: 20130316941Abstract: The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess body weight and associated conditions. The compounds may also be used to improve glycemic control and/or for the treatment of diabetes. The compounds may mediate their effect, inter alia, by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: December 19, 2012Publication date: November 28, 2013Applicants: Boehringer Ingelheim International GmbH, Zealand Pharma A/SInventors: Dieter Wolfgang Hamprecht, Jakob Lind Tolborg, Ditte Riber
-
Publication number: 20130310314Abstract: The present invention relates to a method of preparing a peptide comprising the amino acid sequence His-Gly-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp (SEQ ID NO:1). In particular, the method comprises the steps of providing a first peptide fragment having a first protection group, which peptide fragment is conjugated to a support; providing a second peptide fragment having a second protection group; removing the first protection group from the first peptide fragment; and coupling the second peptide fragment to the N-terminally deprotected, support-conjugated first peptide fragment. The present invention further relates to a method of preparing a pharmaceutical composition containing said peptide.Type: ApplicationFiled: August 30, 2011Publication date: November 21, 2013Applicant: TAKEDA GMBHInventor: Don Wellings
-
Publication number: 20130303436Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of GLP-1, and/or naturally or artificially occurring variants or analogues of GLP-1, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide such as D-Arg-2?6?-Dmt-Lys-Phe-NH2).Type: ApplicationFiled: April 11, 2013Publication date: November 14, 2013Inventor: D. Travis WILSON
-
Patent number: 8580733Abstract: The present invention is related to glucagon-like peptide-1 (GLP-1) and analogues insulinotropic peptides, monoconjugated to biocompatible polymeric molecules by enzymatic direct and site-specific transglutamination reaction as well as their pharmaceutical formulations and delivery systems for therapeutical application in dismetabolic pathologies such as type 2 diabetes.Type: GrantFiled: November 4, 2009Date of Patent: November 12, 2013Assignee: Bio-Ker SRLInventors: Giancarlo Tonon, Gaetano Orsini, Mauro Sergi, Rodolfo Schrepfer, Pierandrea Esposito
-
Patent number: 8575097Abstract: The invention provides a novel Exendin variant and the Exendin variant conjugate conjugating polymer thereon, the pharmaceutical composition comprising them and use of them for treating diseases such as reducing blood glucose, treating diabetes, especially Type II diabetes. The invention also provides the use of Exendin conjugate for lowering body weight.Type: GrantFiled: April 23, 2010Date of Patent: November 5, 2013Assignee: Pegbio Co., Ltd.Inventors: Michael M. Xu, Yongxiang Wang, Yinghui Zhang, Xiaosu Luo, Nian Gong, Lijie Zhang, Xiangjun Zhou
-
Publication number: 20130288960Abstract: The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1 (7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1 (7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1, Chem. 2, and Chem. 3: Chem.: HOOC—(CH2)x—CO—* Chem. 2: HOOC—C6H4-0-(CH2)y—CO—* Chem. 3: R2—C6H4—(CH2)z—CO—*, in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1-5, and R2 is a group having a molar mass not higher than 150 Da; and the linker comprises Chem. 4: *—NH—(CH2)2-(0-(CH2)2)k-0-(CH2)n—CO—*. wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof.Type: ApplicationFiled: November 9, 2011Publication date: October 31, 2013Applicant: Novo Nordisk A/SInventors: Alice Ravn Madsen, Birgit Wieczorek, Jacob Kofoed, Jesper Lau, Jane Spetzler, Janos Tibor Kodra, Lars Linderoth, Patrick William Garibay, Per Sauerberg, Thomas Kruse
-
Publication number: 20130280209Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.Type: ApplicationFiled: April 15, 2013Publication date: October 24, 2013Inventors: Ofer MANDELBOIM, Angel PORGADOR, Yaakov NAPARSTEK, Chamutal GUR
-
Publication number: 20130281368Abstract: A stretching and exercise device has a first strap member having a pair of end portions, a second strap member having a pair of end portions, and a pair of resistance members connected between respective end portions of the first and second strap members. A third strap member has a pair of end portions attached to respective first and second surface portions of the second strap member. A fourth strap member is attached to a third surface portion of the second strap member different from the first and second surface portions thereof.Type: ApplicationFiled: June 24, 2011Publication date: October 24, 2013Applicant: BIOUSIAN BIOSYSTEMS, INC.Inventors: Edward Bilsky, Robin Polt, Hanoch Senderowitz
-
Patent number: 8557769Abstract: The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in the methods of the present invention.Type: GrantFiled: June 27, 2012Date of Patent: October 15, 2013Assignee: Eli Lilly and CompanyInventors: Tamer Coskun, Wolfgang Glaesner
-
Patent number: 8551946Abstract: Provided herein are peptide combinations comprising a GIP agonist peptide and a glucagon antagonist peptide. In some embodiments, the peptide combination is provided as a composition, e.g., a pharmaceutical composition, while in other embodiments, the peptide combination is provided as a kit. In yet other embodiments, the peptide combination is provided as a conjugate, e.g., a fusion peptide, a heterodimer. In specific aspects, the GIP agonist peptide is an analog of native human glucagon. In specific aspects, the glucagon antagonist peptide is an analog of native human glucagon. In some embodiments, the GIP agonist peptide is covalently attached to the glucagon antagonist peptide via a linker. Methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the peptide compositions described herein are further provided.Type: GrantFiled: January 26, 2011Date of Patent: October 8, 2013Assignee: Indiana University Research and Technology CorporationInventors: Richard D. Dimarchi, Tao Ma
-
Patent number: 8546327Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).Type: GrantFiled: June 16, 2009Date of Patent: October 1, 2013Assignee: Indiana University Research and Technology CorporationInventors: Richard D. Dimarchi, David L. Smiley, Maria Dimarchi, Joseph Chabenne, Jonathan Day, James Patterson, Brian Ward
-
Patent number: 8546326Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) at least one neutral diacyl lipid, such as a diacyl glycerol; b) at least one phospholipid, such as a phosphatidyl choline; c) at least one biotolerable solvent, such as an oxygen containing solvent; d) at least one GLP-1 analogue; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, especially in treating diabetes, and to pre-filled administration devices and kits containing the formulations.Type: GrantFiled: June 6, 2006Date of Patent: October 1, 2013Assignee: Camurus ABInventors: Fredrik Joabsson, Markus Johnsson, Fredrik Tiberg
-
Patent number: 8541368Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: GrantFiled: September 21, 2012Date of Patent: September 24, 2013Assignee: Novo Nordisk A/SInventors: Jesper F. Lau, Thomas Kruse, Henning Thoegersen, Ulrich Sensfuss, Peter Kresten Nielsen
-
Patent number: 8536122Abstract: Protracted GLP-1 compounds and therapeutic uses thereof.Type: GrantFiled: March 5, 2012Date of Patent: September 17, 2013Assignee: Novo Nordisk A/SInventors: Jesper Lau, Florencio Zaragoza Doerwald, Paw Bloch, Thomas Kruse Hansen
-
Patent number: 8535715Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.Type: GrantFiled: November 12, 2010Date of Patent: September 17, 2013Assignees: Bristol-Myers Squibb Company, AstraZeneca UK LimitedInventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
-
Patent number: 8536121Abstract: The present invention provides the use of ?arrestin2 protein or its up-regulators for manufacturing a composition for the prevention or treatment of insulin resistance or related disease in mammals. The reagents and the kits for the specific identification of ?arrestin2 protein or its coding gene or transcript are also provided which can be used in diagnosis of insulin resistance or related diseases.Type: GrantFiled: December 3, 2009Date of Patent: September 17, 2013Assignee: Shanghai Institutes for Biological Sciences, CASInventors: Gang Pei, Bing Luan, Jian Zhao
-
Publication number: 20130231282Abstract: The present invention relates to methods of administering hypoglycemic agents and/or GLP-1 agonists.Type: ApplicationFiled: May 4, 2012Publication date: September 5, 2013Inventors: Mark A. Bush, Mary Colleen O'Neill
-
Publication number: 20130225487Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).Type: ApplicationFiled: March 12, 2013Publication date: August 29, 2013Applicant: Pfizer Inc.Inventor: Pfizer Inc.
-
Patent number: 8518876Abstract: The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)x-Peptide (SEQ ID NO: 76), wherein A is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidodiacetic acid group, or 4) a moiety of formula (ZyHisw)p (SEQ ID NO: 50), wherein Z is any amino acid residue other than histidine, His is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if A has alkyl group with 6 to 36 carbon units x is greater than 0; and Cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or N-Arginine or N-lysine, wherein x is an integer between 0-6 and N may be any amino acid or none. The peptide analogs are complexed with polymeric carrier to provide enhanced half-life.Type: GrantFiled: April 27, 2011Date of Patent: August 27, 2013Assignee: Pharmaln CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin
-
Publication number: 20130217622Abstract: The present disclosure relates to an exendin-4 analogue PEGylated with polyethylene glycol or a derivative thereof, a preparation method, and a pharmaceutical composition for prevention or treatment of diabetes containing the same as an active ingredient. According to the present invention, the yield of an exendin-4 analogue can be increased via the selective PEGylation by using exendin-4 in which a cysteine is introduced into #40 site of the C-terminal, and treatment effect of medications can be increased, so that the exendin-4 analogue can be usefully applied as a composition for prevention or treatment of diseases caused by insulin hypersecretion.Type: ApplicationFiled: June 28, 2012Publication date: August 22, 2013Applicant: B & L DELIPHARM, CORP.Inventors: Sung Kwon Lee, Won Bae Kim, Seulki Lee, Tae Hyung Kim
-
Patent number: 8513190Abstract: The present invention provides methods for modification and regulation of type II diabetes by administering to an animal a therapeutically effective amount of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof, where the inhibitor has a Ki for inhibition of DPIV of 10 nM or less; and the inhibitor is administered in an amount sufficient to treat type II diabetes but not sufficient to suppress the immune system of the animal.Type: GrantFiled: November 16, 2011Date of Patent: August 20, 2013Assignees: Trustees of Tufts College, New England Medical Center Hospitals, Inc., 1149336 Ontario, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
-
Publication number: 20130210722Abstract: Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders.Type: ApplicationFiled: March 26, 2013Publication date: August 15, 2013Applicant: ZEALAND PHARMA A/SInventor: ZEALAND PHARMA A/S
-
Publication number: 20130210718Abstract: The invention provides compositions and methods for determining cardiodiabetes status in a subject. The invention also provides compositions and methods for treating a subject experiencing cardiodiabetes.Type: ApplicationFiled: January 24, 2013Publication date: August 15, 2013Applicant: IKFE Institut fur Klinische Forschung und Entwicklung GMBHInventor: IKFE Institut fur Klinische Forschung und Entwicklung GMBH
-
Patent number: 8507429Abstract: The present invention relates to an oligosaccharide chain added GLP-1 peptide that has higher stability in blood than that of GLP-1 and, preferably, exhibits higher activity of controlling blood-sugar levels than that of GLP-1. The present invention relates to an oligosaccharide chain added GLP-1 peptide having GLP-1 activity, wherein at least one amino acid is substituted with an oligosaccharide chain added amino acid, in: (a) GLP-1; (b) a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or (c) a GLP-1 analog.Type: GrantFiled: June 2, 2011Date of Patent: August 13, 2013Assignee: Glytech, Inc.Inventors: Yasuhiro Kajihara, Takashi Tsuji, Izumi Sakamoto, Yuri Nambu, Kazuhiro Fukae, Katsunari Tezuka, Hiroaki Asai
-
Patent number: 8507428Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.Type: GrantFiled: December 20, 2011Date of Patent: August 13, 2013Assignee: Indiana University Research and Technology CorporationInventors: Richard D. DiMarchi, Brian P. Ward
-
Publication number: 20130203659Abstract: GLP-1 compounds comprising GLP-1 analogs and methods of using the GLP-1 compounds for treating metabolic disorders, enhancing insulin expression, and promoting insulin secretion in a patient are provided.Type: ApplicationFiled: October 15, 2012Publication date: August 8, 2013Inventors: Leslie P. MIRANDA, Katherine Ann WINTERS, Murielle VENIANT-ELLISON
-
Publication number: 20130203666Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.Type: ApplicationFiled: August 27, 2012Publication date: August 8, 2013Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Elisabeth NIEMOELLER, Isabel MÜEHLEN-BARTMER, Louise SILVESTRE, Gabor BOKA, Patrick MIOSSEC
-
Publication number: 20130203651Abstract: The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.Type: ApplicationFiled: January 21, 2011Publication date: August 8, 2013Applicant: SANOFIInventors: Mark Sommerfeld, Hans-Ludwig Schaefer, Oliver Boscheinen, Paul Habermann, Ercole Rao, Matthias Dreyer
-
Publication number: 20130203660Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).Type: ApplicationFiled: January 9, 2013Publication date: August 8, 2013Applicant: Indiana University Research and Technology CorporationInventor: Indiana University Research and Technology Corporation
-
Patent number: 8501693Abstract: The present invention relates to altering the concentration of fibrinogen, specifically, for example, by decreasing fibrinogen concentration. The present invention also relates to methods for improving the cardiovascular risk profile of a subject by decreasing fibrinogen concentration.Type: GrantFiled: August 6, 2007Date of Patent: August 6, 2013Assignees: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals LPInventors: Dennis Kim, Michael Trautmann
-
Publication number: 20130195939Abstract: This invention provides compositions comprising a byetta, fish oil, and a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral or rectal administration of a byetta.Type: ApplicationFiled: April 2, 2013Publication date: August 1, 2013Applicant: Oramed Ltd.Inventor: Oramed Ltd.
-
Publication number: 20130196898Abstract: The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.Type: ApplicationFiled: November 26, 2010Publication date: August 1, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Klaus Dugi, Eva Ulrike Graefe-Mody, Michael Mark, Hans-Juergen Woerle, Heike Zimdahl-Gelling
-
Patent number: 8497240Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.Type: GrantFiled: August 17, 2007Date of Patent: July 30, 2013Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Odile Esther Levy, Alain D. Baron, Lawrence J. D'Souza, Mary Erickson, Soumitra S. Ghosh, Michael R. Hanley, Samuel Janssen, Carolyn M. Jodka, Diana Y. Lewis, Christine M. Mack, David G. Parkes, Richard A. Pittner, Christopher J. Soares, Ved Srivastava, Andrew A. Young, Thao Le
-
Publication number: 20130190233Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.Type: ApplicationFiled: January 18, 2013Publication date: July 25, 2013Applicant: CUREDM GROUP HOLDINGS, LLCInventor: CUREDM GROUP HOLDINGS, LLC